Fachbereich Physik and Wissenschaftliches Zentrum für Materialwissenschaften, Philipps Universität Marburg, 35037 Marburg, Germany.
Pharmacol Res. 2010 Aug;62(2):115-25. doi: 10.1016/j.phrs.2010.01.009. Epub 2010 Jan 25.
In this review we would like to aim at pharmaceuticals engineered on the nanoscale, i.e. pharmaceuticals where the nanomaterial plays the pivotal therapeutic role or adds additional functionality to the previous compound. Those cases would be considered as nanopharmaceuticals. The development of inorganic systems is opening the pharmaceutical nanotechnology novel horizons for diagnosis, imaging and therapy mainly because of their nanometer-size and their high surface area to volume ratios which allow for specific functions that are not possible in the micrometer-size particles. This review will focus on pharmaceutical forms that are based on inorganic nanoparticles where the nanosize of the inorganic component provides unique characteristics to the pharmaceutical form. Several examples of these systems that are either in pre-clinical investigation and under examination by the Food and Drug Administration (FDA) or that have been already approved by the FDA and are in clinical practice today like Gastromark, NanoTherm, Colloidal Gold for Lateral Flow tests, HfO-NPs, BioVant will be described and reviewed.
在这篇综述中，我们希望着眼于纳米尺度上设计的药物，即纳米材料发挥关键治疗作用或为先前的化合物增加额外功能的药物。这些情况将被视为纳米药物。无机系统的发展为诊断、成像和治疗开辟了新的药物纳米技术领域，主要是因为它们的纳米尺寸和高表面积与体积比，使它们具有在微米级颗粒中不可能实现的特定功能。本综述将集中于基于无机纳米粒子的药物形式，其中无机成分的纳米尺寸为药物形式提供了独特的特性。本文将描述和回顾几种处于临床前研究和美国食品和药物管理局（FDA）审查阶段或已经获得 FDA 批准并在临床上应用的此类系统，如 Gastromark、NanoTherm、侧向流动试验胶体金、HfO-NPs、BioVant。
